Skip to main content

Table 3 Univariate and multivariate analyses for the PFS and OS of patients with tissue detected mutation and the use of TKIs as first-line therapy

From: Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Variable

PFS

OS

Univariate

Multivariate

Univariate

Multivariate

HR (95% CI)

P valuea

HR (95% CI)

P valuea

HR (95% CI)

P valuea

HR (95% CI)

P valuea

Age

1.000 (0.986–1.014)

0.980

0.993 (0.977–1.009)

0.381

1.008 (0.987–1.029)

0.480

0.996 (0.973–1.020)

0.757

Sex (men vs. women)

1.149 (0.830–1.590)

0.404

1.520 (0.916–2.522)

0.105

1.540 (0.992–2.393)

0.055

1.776 (0.890–3.544)

0.103

Smoking status (ever vs. never)

0.907 (0.628–1.311)

0.604

0.616 (0.363–1.044)

0.072

1.299 (0.807–2.091)

0.282

0.835 (0.405–1.722)

0.626

ECOG PS (2 vs. 0-1)

0.969 (0.523–1.796)

0.921

1.019 (0.536–1.935)

0.955

1.054 (0.454–2.447)

0.903

1.281 (0.531–3.091)

0.582

EGFR-TKI (erlotinib vs. gefitinib)

0.828 (0.531–1.291)

0.405

0.765 (0.448–1.307)

0.327

1.862 (0.581–5.962)

0.295

0.756 (0.357–1.603)

0.466

EGFR-TKI (icotinib vs. gefitinib)

0.652 (0.359–1.184)

0.160

0.702 (0.362–1.361)

0.295

1.917 (0.551–6.664)

0.306

0.255 (0.063–1.037)

0.056

Stage (IIIB vs. IV)

0.552 (0.203–1.498)

0.243

0.402 (0.119–1.356)

0.142

0.878 (0.276–2.795)

0.826

0.600 (0.144–2.506)

0.483

EGFR mutation (exon 19 del vs. L858R mutation)

0.705 (0.509–0.976)

0.035

0.631 (0.432–0.920)

0.017

0.878 (0.563–1.370)

0.566

0.671 (0.397–1.133)

0.135

  1. PFS progression-free survival, OS overall survival, HR hazard ratio, 95% CI 95% confidence interval, ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor
  2. aAnalyzed by using univariate and multivariate COX regression adjusted for age, sex, smoking status, ECOG PS, EGFR-TKIs, and stage